Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
一项针对化疗难治性结直肠癌(CRC)患者的卡博替尼联合度伐利尤单抗II期临床试验的临床和生物标志物结果:CAMILLA CRC队列
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-024-45960-2
Saeed, Anwaar; Park, Robin; Pathak, Harsh; Al-Bzour, Ayah Nedal; Dai, Junqiang; Phadnis, Milind; Al-Rajabi, Raed; Kasi, Anup; Baranda, Joaquina; Sun, Weijing; Williamson, Stephen; Chiu, Yu-Chiao; Osmanbeyoglu, Hatice Ulku; Madan, Rashna; Abushukair, Hassan; Mulvaney, Kelly; Godwin, Andrew K; Saeed, Azhar